PMID- 22244918
OWN - NLM
STAT- MEDLINE
DCOM- 20120611
LR  - 20120220
IS  - 1879-1166 (Electronic)
IS  - 0198-8859 (Linking)
VI  - 73
IP  - 3
DP  - 2012 Mar
TI  - High frequency of human leukocyte antigen class II DRB1*1602 haplotype in Greek 
      patients with myelodysplastic syndrome and of DRB1*1501 in the low-risk subgroup.
PG  - 278-81
LID - 10.1016/j.humimm.2011.12.013 [doi]
AB  - Myelodysplastic syndromes (MDS) comprise a heterogenous group of clonal 
      hematopoietic disorders in which the immune-mediated pathogenetic mechanisms are 
      under investigation. Overrepresentation of human leukocyte antigen (HLA)-DR2 and 
      its serologic split HLA-DR15 has been associated with low-risk MDS in certain 
      ethnic groups and has been proposed as a predictive factor for a favorable 
      response to immunomodulatory treatment. Because the HLA-DRB1*15 haplotype does 
      not predominate in the Greek population, we investigated the frequency of 
      HLA-DRB1 alleles among 114 patients of Greek origin suffering from various types 
      of MDS: 36 refractory anemia (RA), 24 refractory anemia with ringed sideroblasts 
      (RARS), 19 refractory anemia with excess of blasts (RAEB), 14 refractory anemia 
      with excess of blasts in transformation (RAEB-t), 14 chronic myelomonocytic 
      leukemia, and 7 hypoplastic MDS patients. HLA-DRB1 molecular typing was performed 
      with polymerase chain reaction-sequence specific oligonucleotides and results 
      were compared with that from a previously reported control Greek population. 
      HLA-DRB1*1602 was the only allele that was significantly overrepresented in Greek 
      MDS patients as a whole, whereas HLA-DRB1*1501 allele frequency was significantly 
      higher in Greek patients with low-risk myelodysplasia. Our results suggest the 
      possible value of HLA-DR15 and HLA-DR16 as determinants for immunomodulatory 
      interventions, at least for Greek patients with low-risk MDS.
CI  - Copyright A(c) 2012 American Society for Histocompatibility and Immunogenetics. 
      Published by Elsevier Inc. All rights reserved.
FAU - Kritikou-Griva, Elpiniki
AU  - Kritikou-Griva E
AD  - Department of Laboratory Hematology, Athens Regional General Hospital G. 
      Gennimatas, Athens 11527, Greece.
FAU - Spyropoulou-Vlachou, Maria
AU  - Spyropoulou-Vlachou M
FAU - Tsagarakis, Nikolaos J
AU  - Tsagarakis NJ
FAU - Goumakou, Eleni
AU  - Goumakou E
FAU - Vrani, Vasiliki
AU  - Vrani V
FAU - Galanopoulos, Athanasios
AU  - Galanopoulos A
FAU - Papadhimitriou, Stefanos I
AU  - Papadhimitriou SI
FAU - Androutsos, George
AU  - Androutsos G
FAU - Paterakis, George
AU  - Paterakis G
FAU - Stavropoulos-Giokas, Catherine
AU  - Stavropoulos-Giokas C
LA  - eng
PT  - Journal Article
DEP - 20111227
PL  - United States
TA  - Hum Immunol
JT  - Human immunology
JID - 8010936
RN  - 0 (HLA-DRB1 Chains)
RN  - 0 (HLA-DRB1*15:01 antigen)
SB  - IM
MH  - Aged
MH  - Female
MH  - Gene Frequency
MH  - Genetic Association Studies
MH  - Greece
MH  - HLA-DRB1 Chains/*genetics/metabolism
MH  - Histocompatibility Testing
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myelodysplastic Syndromes/*diagnosis/epidemiology/*genetics/physiopathology
MH  - Pathology, Molecular
MH  - Prognosis
MH  - Risk
EDAT- 2012/01/17 06:00
MHDA- 2012/06/12 06:00
CRDT- 2012/01/17 06:00
PHST- 2011/08/03 00:00 [received]
PHST- 2011/12/15 00:00 [revised]
PHST- 2011/12/21 00:00 [accepted]
PHST- 2012/01/17 06:00 [entrez]
PHST- 2012/01/17 06:00 [pubmed]
PHST- 2012/06/12 06:00 [medline]
AID - S0198-8859(11)00604-5 [pii]
AID - 10.1016/j.humimm.2011.12.013 [doi]
PST - ppublish
SO  - Hum Immunol. 2012 Mar;73(3):278-81. doi: 10.1016/j.humimm.2011.12.013. Epub 2011 
      Dec 27.